# The Marine Natural Compound Aplysinamisine I Selectively Induces Apoptosis and Exhibits Synergy with Taxol™ in Triple-Negative Breast Cancer Spheroids

**Authors:** Esther A. Guzmán, Tara A. Peterson, Dedra K. Harmody, Amy E. Wright

PMC · DOI: 10.3390/md23100380 · Marine Drugs · 2025-09-26

## TL;DR

A marine compound called Aplysinamisine I selectively kills triple-negative breast cancer cells and works well with Taxol™, a cancer drug.

## Contribution

Aplysinamisine I is shown to induce apoptosis in 3D TNBC spheroids and synergize with Taxol™, offering a new potential treatment approach.

## Key findings

- Aplysinamisine I induces apoptosis in MDA-MB-268 spheroids with an IC50 of 2.9 ± 0.28 µM.
- The compound shows synergy with Taxol™ in both MDA-MB-231 and MDA-MB-468 cell lines.
- Proteomic analysis suggests a potential mode of action involving nucleophosmin inhibition.

## Abstract

Triple-negative breast cancers (TNBC) lack estrogen, progesterone, and express little, if any, HER2 receptors on their surface. No targeted therapies exist for this aggressive form of breast cancer. A library of enriched fractions from marine organisms was screened in a multi-parametric cytotoxicity assay using MDA-MB-231 and MDA-MB-468 TNBC cells, grown as spheroids (3D cultures). Spheroids better resemble tumors and are considered more clinically predictive. The assay measures apoptosis via the cleavage of caspase 3/7, viability via DNA content, and loss of membrane integrity via 7AAD staining at 24 h of treatment. Fractions were also tested in a traditional 2D MTT assay at 72 h. A fraction from the sponge Aplysina was active in the 3D assay. Aplysinamisine I was identified as the compound responsible for the activity. Aplysinamisine I induces apoptosis in MDA-MB-268 spheroids with an IC50 of 2.9 ± 0.28 µM at 24 h. This novel activity is the most potent for the compound to date. Its IC50 in the MTT assay at 72 h is >80 µM. Striking synergy with Taxol™ is shown in both cell lines. Proteomic analysis led to a differential protein expression profile. Through bioinformatics, this profile led to the hypothesis that the inhibition of nucleophosmin is the potential mode of action of the compound. However, initial studies show only a modest decrease in nucleophosmin expression in spheroids treated with aplysinamisine I.

## Linked entities

- **Chemicals:** Aplysinamisine I (PubChem CID 23427561), Taxol™ (PubChem CID 36314)
- **Diseases:** triple-negative breast cancer (MONDO:0005494)

## Full-text entities

- **Genes:** NPM1 (nucleophosmin 1) [NCBI Gene 4869] {aka B23, NPM}, ERBB2 (erb-b2 receptor tyrosine kinase 2) [NCBI Gene 2064] {aka CD340, HER-2, HER-2/neu, HER2, MLN 19, MLN-19}
- **Diseases:** Triple (MESH:C536008), TNBC (MESH:D064726), cytotoxicity (MESH:D064420), Breast Cancer (MESH:D001943), tumors (MESH:D009369)
- **Chemicals:** 7AAD (MESH:C025942), MTT (MESH:C070243), Spheroids (-), Aplysinamisine I (MESH:C082607), Taxol (MESH:D017239)
- **Species:** Aplysina (genus) [taxon 121476]
- **Cell lines:** MDA-MB-268 — Homo sapiens (Human), Finite cell line (CVCL_2Z46), MDA-MB-231 — Homo sapiens (Human), Breast adenocarcinoma, Cancer cell line (CVCL_0062), MDA-MB-468 — Homo sapiens (Human), Breast adenocarcinoma, Cancer cell line (CVCL_0419)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12565524/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12565524/full.md

## References

55 references — full list in the complete paper: https://tomesphere.com/paper/PMC12565524/full.md

---
Source: https://tomesphere.com/paper/PMC12565524